SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today…
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under…
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,…
Latest News List Featured Article
Latest News Blocks Featured
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
View Press ReleaseLatest News Blocks
Latest Presentation / Event
Upcoming Event
2024 American Society of Clinical Oncology Annual Meeting
IR Stock Info
Email Alerts
Sign up today and receive company updates straight to your inbox.
Financial Results w Email Alerts
Q3 2024
Quarter Ended March 31, 2024
Latest Annual Filing
For Fiscal Year Ending Jun 30, 2023
Report Links
Upcoming Events
2024 American Society of Clinical Oncology Annual Meeting
Upcoming Event
2024 American Society of Clinical Oncology Annual Meeting
May 31 – June 4, 2024